{
    "2018-04-04": [
        [
            {
                "time": "2018-04-09",
                "original_text": "EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Johnson & Johnson of Commencement of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 9, 2018 – JNJ",
                "features": {
                    "keywords": [
                        "Class Action",
                        "Lawsuit",
                        "Johnson & Johnson"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-28",
                "original_text": "NYSE trader: Here are the real risks to the U.S. economy",
                "features": {
                    "keywords": [
                        "risks",
                        "U.S. economy"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "economy"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "Allergan's Vraylar Meets Endpoints in Bipolar I Phase III",
                "features": {
                    "keywords": [
                        "Vraylar",
                        "Bipolar I",
                        "Phase III"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-16",
                "original_text": "AstraZeneca's (AZN) Bydureon Gets FDA Nod for Expanded Use",
                "features": {
                    "keywords": [
                        "AstraZeneca",
                        "Bydureon",
                        "FDA",
                        "Expanded Use"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-25",
                "original_text": "Johnson & Johnson’s Quarterly Revenue Trend in 2017",
                "features": {
                    "keywords": [
                        "Quarterly Revenue",
                        "Trend",
                        "2017"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-03-27",
                "original_text": "J&J Jury Set to Weigh Banker's Claims Baby Powder Caused Cancer",
                "features": {
                    "keywords": [
                        "J&J",
                        "Baby Powder",
                        "Cancer"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-04-05",
                "original_text": "Bristol-Myers Squibb Company (BMY) Ex-Dividend Date Scheduled for April 05, 2018",
                "features": {
                    "keywords": [
                        "Bristol-Myers Squibb",
                        "Ex-Dividend",
                        "Date"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-03-20",
                "original_text": "Analysts’ Recommendations for Johnson & Johnson in March 2018",
                "features": {
                    "keywords": [
                        "Analysts",
                        "Recommendations",
                        "March 2018"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}